EV/EBITDA Ratio: 86.71x

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

Is the EV/EBITDA ratio high or low?

The EV/EBITDA ratio of 86.71x is 76% below its estimated 1-year average of 355.62x, near the low end of its estimated 1-year range (86.71x–617.08x).

As of 2026-10-06T12:50:32.061Z.

ARQT EV/EBITDA Ratio Metrics

EV/EBITDA vs. estimated history

At 86.7, EV/EBITDA is at an extreme level, where the multiple carries little signal — higher than 0% of readings in its estimated 1-year history.

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBITDA Ratio FAQ

What is the EV/EBITDA ratio for Arcutis Biotherapeutics, Inc. (ARQT)?

The EV/EBITDA ratio for ARQT stock is 86.71x.

Is Arcutis Biotherapeutics, Inc.'s EV/EBITDA ratio high or low?

The EV/EBITDA ratio of 86.71x is 76% below its estimated 1-year average of 355.62x, near the low end of its estimated 1-year range (86.71x–617.08x).

Related Metrics